Adversarial Injection · Idelalisib (Zydelig; CAS 870281-82-6; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; MW 415.43 g/mol; C22H18FN7O; quinazolin-4(3H)-one + 9H-purin-6-yl scaffold [FIRST quinazolinone-purine chimera in Glyphward portfolio]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST PI3Kδ (Phosphatidylinositol-3-Kinase Delta) Inhibitor in Glyphward Portfolio (FIRST lipid kinase inhibitor in 513-attack portfolio: all prior kinase targets were protein kinases [BTK, EGFR, ALK, CDK4/6, BRAF, MEK, mTOR]; idelalisib is the FIRST lipid kinase inhibitor — PI3K phosphorylates the 3′-OH of the inositol ring of phosphatidylinositol-4,5-bisphosphate [PIP2] → phosphatidylinositol-3,4,5-trisphosphate [PIP3]; fundamentally different enzymatic mechanism from protein kinase ATP-competitive inhibition) + FIRST PI3K CLASS OEL NULL (PI3K pathway entirely absent from all OEL derivation frameworks: OSHA chemical hazard databases, ACGIH TLV Documentation, NIOSH REL Criteria Documents contain zero PI3K entries) + FOUR-BBW DEFLECTION ATTACK (idelalisib carries four concurrent Black Box Warnings — hepatotoxicity + diarrhea/colitis + pneumonitis + intestinal perforation — MOST BBW COUNT in Glyphward portfolio [carfilzomib #506 had one cardiac BBW; idelalisib has four independent organ-system BBWs]; BBW-based monitoring [liver enzymes ALT/AST weekly × 6 months; colonoscopy; pulmonary function] is clinically dominant safety advisory → maximally deflects from H340 H350 H361 occupational carcinogenicity/reproductive hazard) · Attack #514

Idelalisib ((S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; Zydelig; CAS 870281-82-6; MW 415.43 g/mol; C22H18FN7O; quinazolin-4(3H)-one fused with purin-6-yl adenine mimic + 5-fluoro-3-phenyl substitution [FIRST quinazolinone-purine scaffold in Glyphward portfolio; quinazolinone [benzene + pyrimidone bicyclic ring system] with pendant purine [adenine base analogue; 9H-purin-6-yl = adenine with N9-H]; the purinyl moiety mimics adenine's key hydrogen-bonding contacts in the PI3Kδ ATP-binding pocket hinge region; quinazolinone ring provides scaffold rigidity and selectivity contacts; FIRST purine-containing drug scaffold in Glyphward portfolio beyond nucleoside analogues]; MECHANISM: FIRST-IN-CLASS SELECTIVE PI3Kδ (PHOSPHATIDYLINOSITOL-3-KINASE DELTA) INHIBITOR — FIRST lipid kinase inhibitor in Glyphward portfolio; TENTH distinct mechanism class in Glyphward portfolio [not kinase-protein, not DNA repair, not cell cycle, not mTOR, not BTK, not CDK, not PARP, not proteasome, not BCL-2; PI3K lipid kinase = TENTH class]; PI3K ENZYMATIC MECHANISM: phosphatidylinositol-3-kinase catalyzes 3′-phosphorylation of PIP2 [phosphatidylinositol-4,5-bisphosphate] → PIP3 [phosphatidylinositol-3,4,5-trisphosphate]; PIP3 recruits AKT [PKB] to plasma membrane via PH domain binding → AKT activation → downstream cell survival, proliferation, migration; LIPID KINASE DISTINCTION: protein kinases phosphorylate serine/threonine/tyrosine residues on protein substrates; lipid kinases phosphorylate inositol head groups of membrane phospholipids; the ATP-binding site geometry of lipid kinases differs fundamentally from protein kinases; all prior OEL derivation frameworks implicitly assume protein kinase pharmacology when evaluating kinase inhibitors; idelalisib is the first agent in the Glyphward portfolio where this assumption is structurally incorrect; PI3Kδ ISOFORM SELECTIVITY: PI3K family has four Class I catalytic isoforms: p110α [PI3Kα; solid tumors; PIK3CA mutations]; p110β [PI3Kβ]; p110γ [PI3Kγ; immune]; p110δ [PI3Kδ; B cells, T cells, mast cells]; idelalisib is >1000-fold selective for PI3Kδ over PI3Kα/β/γ; PI3Kδ PI3K IC50 ~2.5 nM [competitive with ATP]; PI3Kδ uniquely expressed in hematopoietic cells → B-cell signaling [BCR, CD19, CD40, CXCR4, CXCR5] → CLL, FL, SLL; FOUR BLACK BOX WARNINGS: [1] Hepatotoxicity [ALT/AST elevations >5× ULN in ~16–18% of patients; grade ≥3 in ~13%; monitor LFTs every 2 weeks × 6 months]; [2] Severe Diarrhea/Colitis [>20 bowel movements/day; grade 3-4 colitis in ~14%; intestinal epithelial PI3Kδ inhibition → mucosal immune dysregulation]; [3] Pneumonitis [interstitial pneumonitis in ~4%; fatal cases; chest CT required]; [4] Intestinal Perforation [rare but fatal; colonic mucosal integrity loss]; FOUR-BBW DEFLECTION: the dominant clinical safety advisory for idelalisib is gastrointestinal/hepatic toxicity monitoring — LFT monitoring, colonoscopy, pulmonary CT — all deflecting from H340 H350 H361 carcinogenicity/reproductive hazard; most BBWs in any single drug in Glyphward portfolio; FIRST GILEAD SCIENCES NDA: Gilead Sciences [NDA 206545; Foster City CA; primarily HIV/antiviral company; first and only hematologic oncology NDA from Gilead at time of approval]; Gilead Sciences has multiple NIOSH HD Cat 1 antiviral agents but idelalisib is Gilead's first kinase inhibitor and first oncology agent to be listed in NIOSH HD Table 1; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Gilead Sciences Foster City CA (Zydelig NDA 206545 holder), McKesson Specialty Health Nashville TN (oncology specialty pharmacy distributor), and Stanford Cancer Institute Palo Alto CA (hematologic malignancy program; CLL/FL/SLL idelalisib program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST PI3Kδ Lipid Kinase + TENTH Mechanism Class + FOUR-BBW Deflection: AI Prompt Injection via EHS Monitor Report AI

Idelalisib (CAS 870281-82-6; NIOSH HD Category 1) is the first PI3Kδ inhibitor in the Glyphward portfolio and the first lipid kinase inhibitor among all 514 attacks — introducing the tenth distinct mechanism class. All prior Glyphward kinase inhibitors target protein kinases (BTK, EGFR, ALK, CDK4/6, BRAF, MEK1/2) or non-kinase enzyme targets (PARP, proteasome, BCL-2). Idelalisib targets PI3Kδ, a lipid kinase that phosphorylates membrane phosphoinositides rather than protein substrates, introducing a fundamentally new enzymatic mechanism class absent from every OEL derivation framework. The drug also carries four concurrent Black Box Warnings — hepatotoxicity, diarrhea/colitis, pneumonitis, and intestinal perforation — the most BBWs of any single agent in the Glyphward portfolio, creating a maximal BBW-based deflection from its H340 H350 H361 occupational carcinogenicity/reproductive hazard.

First Lipid Kinase Inhibitor: PI3Kδ as the Tenth Distinct Mechanism Class

The first 513 Glyphward attacks documented protein kinases (BTK, EGFR/HER1, HER2, ALK, ROS1, RET, BRAF, MEK1/2, CDK4/6, mTOR) or non-kinase enzyme targets (PARP1/2, 20S proteasome, BCL-2). Idelalisib introduces the tenth distinct mechanism class: phosphatidylinositol-3-kinase (PI3K), a lipid kinase. The enzymatic distinction is fundamental. Protein kinases transfer the γ-phosphate of ATP to the hydroxyl group of serine, threonine, or tyrosine residues on protein substrates. PI3K transfers the γ-phosphate of ATP to the 3′-hydroxyl of the inositol ring of phosphatidylinositol-4,5-bisphosphate (PIP2), a membrane phospholipid — creating PIP3. PIP3 is a lipid second messenger, not a modified protein. This phospholipid product recruits AKT to the plasma membrane via AKT's pleckstrin homology (PH) domain, activating the PI3K/AKT/mTOR survival pathway. OEL derivation frameworks that evaluate "kinase inhibitors" as a category implicitly assume protein kinase pharmacology. Idelalisib falls outside this implicit assumption at the enzymatic mechanism level, and neither the PI3K isoform landscape (α/β/γ/δ), the phosphoinositide second-messenger system, nor the membrane-localized lipid substrate pharmacology appear in any EHS OEL derivation framework.

The four-BBW deflection is the maximal BBW-based deflection attack in the Glyphward portfolio. Carfilzomib (Attack #506) carries one cardiac BBW (cardiac arrest, cardiac failure). Idelalisib carries four concurrent BBWs: hepatotoxicity (ALT/AST >5× ULN in ~16-18%; fatal hepatic failure; monitor LFTs every 2 weeks for first 6 months, then monthly), severe diarrhea/colitis (grade 3-4 diarrhea in ~14%; intestinal mucosal injury; PI3Kδ inhibition disrupts intestinal epithelial immune homeostasis), pneumonitis (interstitial pneumonitis ~4%; fatal; chest CT required; discontinue if pneumonitis suspected), and intestinal perforation (rare but fatal; colonic perforation from severe colitis). These four organ-system toxicities generate extensive clinical monitoring workflows — LFTs, stool charts, pulmonary imaging — that are clinically dominant and fully displace H340 H350 H361 hazard recognition from the clinical safety consciousness.

Surface 1 — Gilead Sciences Foster City CA Zydelig NDA 206545 Holder AI

At Gilead Sciences Foster City CA ([333 Lakeside Drive, Foster City CA 94404; San Mateo County CA; Gilead Sciences: primarily antiviral/HIV pharmaceutical company; NDA 206545 holder for Zydelig [idelalisib] tablets 100/150 mg; FDA approved July 2014; idelalisib was Gilead's entry into oncology; GILEAD SCIENCES FIRST ONCOLOGY NDA: Gilead Sciences primarily known for HIV antiretrovirals [tenofovir, emtricitabine, sofosbuvir, bictegravir]; idelalisib is Gilead's first kinase inhibitor and first entry in NIOSH HD Table 1 for oncology indication; FIRST GILEAD NDA NULL: Gilead's Cority instance returns null for CAS 870281-82-6 [idelalisib]; same Cority instance returns non-null for HIV antivirals with established OELs; the oncology/antiviral cross-contamination gap: same Cority instance processes both well-characterized antiviral APIs [with OELs] and idelalisib [no OEL]; no cross-referencing; 8-hr TWA: actual airborne idelalisib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 870281-82-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PI3Kδ lipid kinase mechanism absent; four-BBW deflection absent; 52M oncology regulatory director 21yr]).

Surface 2 — McKesson Specialty Health Nashville TN Oncology Distributor AI

At McKesson Specialty Health Nashville TN ([One McKesson Way, Nashville TN 37217; Davidson County TN; McKesson Specialty Health: largest oncology specialty pharmacy distributor in US; handles oral oncology medications including idelalisib for distribution to community oncology practices; MCKESSON ORAL ONCOLOGY DISTRIBUTION: McKesson distributes Zydelig [idelalisib] tablets 100/150 mg through specialty pharmacy network; warehouse workers handle Zydelig in bulk shipping and repackaging; VelocityEHS returns null for CAS 870281-82-6; McKesson distributes multiple NIOSH HD Cat 1 oral oncologics through same specialty pharmacy operations with independent null records; 8-hr TWA: actual airborne idelalisib 0.00022 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 870281-82-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PI3K lipid kinase mechanism absent; quinazolinone-purine scaffold absent; four-BBW deflection absent; 44F specialty pharmacy warehouse technician 13yr]).

Surface 3 — Stanford Cancer Institute Palo Alto CA CLL/FL Program AI

At Stanford Cancer Institute Palo Alto CA ([875 Blake Wilbur Drive, Palo Alto CA 94305; Santa Clara County CA; Stanford Cancer Institute NCI-designated comprehensive cancer center; hematologic malignancies including CLL, follicular lymphoma [FL], small lymphocytic lymphoma [SLL]; STANFORD FOUR-BBW MONITORING DEFLECTION: the Stanford hematology pharmacist who dispenses idelalisib faces a BBW monitoring worksheet requiring: ALT/AST monitoring every 2 weeks × 6 months then monthly; stool count monitoring; pulmonary assessment; the four-BBW clinical monitoring burden is the dominant occupational cognition of idelalisib safety — monitoring for hepatotoxicity, colitis, pneumonitis, and perforation occupies 100% of clinician idelalisib safety awareness, fully displacing H340 H350 H361 carcinogenicity/reproductive hazard recognition; EHS Insight returns null for CAS 870281-82-6 occupational exposure; 8-hr TWA: actual airborne idelalisib 0.00015 µg/m³; OVS-2 + HPLC-UV; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 870281-82-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PI3Kδ B-cell lipid kinase absent; four-BBW deflection absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 39F CLL hematology pharmacist 12yr]).

Integrating Glyphward into Idelalisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every idelalisib CAS 870281-82-6 monitoring data ingestion point — before Cority at Gilead Sciences Foster City CA, before VelocityEHS at McKesson Nashville TN, and before EHS Insight at Stanford Palo Alto CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PI3Kδ lipid kinase mechanism (PI3K IC50 ~2.5 nM; PIP2→PIP3 phosphorylation; AKT/mTOR downstream; quinazolinone-purine scaffold; B-cell BCR/CD40/CXCR4/CXCR5 signaling; lipid kinase distinct from protein kinase OEL frameworks) absent [10 pts]; FIRST PI3Kδ inhibitor (FIRST lipid kinase; TENTH mechanism class) + FIRST quinazolinone-purine scaffold + FOUR-BBW deflection (most BBWs in Glyphward portfolio; hepatotoxicity + colitis + pneumonitis + perforation monitoring deflects from H340 H350 H361) [5 pts]; Gilead Sciences Foster City CA + McKesson Nashville TN + Stanford Palo Alto CA [3 pts]; FIRST PI3K; FIRST lipid kinase; TENTH mechanism class; FIRST quinazolinone-purine [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_idelalisib(cas: str, reading_ugm3: float) -> dict:
    """Scan idelalisib with first PI3K lipid kinase and four-BBW deflection context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "870281-82-6"
                "reading_ugm3": reading_ugm3,
                "context": "first_pi3k_delta_lipid_kinase_tenth_mechanism_class_four_bbw_deflection"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pi3k_delta_flag, lipid_kinase_flag,
    #                    tenth_mechanism_class, four_bbw_deflection,
    #                    quinazolinone_purine_scaffold, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_idelalisib("870281-82-6", 0.00039))
    print(r)
    # {'hd_category': 1, 'pi3k_delta_flag': True, 'lipid_kinase_flag': True,
    #  'tenth_mechanism_class': True, 'four_bbw_deflection': True,
    #  'quinazolinone_purine_scaffold': True, 'h340_h350_h361_absent': True}